Pipeline A robust pipeline to treat the most resistant cancers and neurological diseases Hard to treat cancers and neurodegenerative diseases demand a diverse arsenal of novel therapeutic approaches. From monoclonal and bispecific antibodies, to antibody drug conjugates, discover what we have in development. Fully-owned clinical assets PD-1/VEGF Preclinical IND-enabling Phase 1 Phase 2 Phase 3 Worldwide Rights AI-081 Solid tumors Preclinical IND-enabling Phase 1 Phase 2 Phase 3 SIGLEC10 Preclinical IND-enabling Phase 1 Phase 2 Phase 3 Worldwide Rights ONC-841 Solid tumors Preclinical IND-enabling Phase 1 Phase 2 Phase 3 ONC-841 Alzheimer’s disease Preclinical IND-enabling Phase 1 Phase 2 Phase 3 Fully-owned pre-clinical assets CD24 Preclinical IND-enabling Phase 1 Phase 2 Phase 3 Worldwide Rights ONC-783 Hematologic malignancies Preclinical IND-enabling Phase 1 Phase 2 Phase 3 ONC-784 Solid tumors Preclinical IND-enabling Phase 1 Phase 2 Phase 3 Late-Stage Clinical Asset in Partnership with BioNTech CTLA-4 Preclinical IND-enabling Phase 1 Phase 2 Phase 3 Worldwide Rights Gotistobart(ONC-392) 2L IO-resistant sq NSCLC Preclinical IND-enabling Phase 1 Phase 2 Phase 3 Gotistobart(ONC-392)* Advanced solid tumors Preclinical IND-enabling Phase 1 Phase 2 Phase 3 ±pembrolizumab* Gotistobart(ONC-392) mCRPC Preclinical IND-enabling Phase 1 Phase 2 Phase 3 +Pluvicto *In partnership with Clinical trials recruiting now We are currently recruiting patients for 4 clinical trials in a range of indications. If you or someone you care about is battling cancer, we welcome you to learn more and get in touch. BIPAVE-001Safety, Pharmacokinetics, and Efficacy of AI-081, a Bispecific Antibody for PD-1 And VEGF in Advanced Solid TumorsIndications: metastatic disease or locally advanced solid tumors Learn more PRESERVE-004A Phase 2 study that compares two doses of gotistobart in combination with a fixed dose of pembrolizumabIndications: Platinum-resistant ovarian cancer Learn more PRESERVE-001A Phase 1 open-label study of gotistobart as a monotherapy and in combination with PembrolizumabIndications: Non Small Cell Lung Cancer, Metastatic Melanoma, Metastatic Head and Neck Carcinoma, Metastatic Renal Cell Carcinoma, Metastatic Colorectal Cancer, Sarcomas, Metastatic Prostate Cance, Ovarian Cance, Small Cell Lung Cancer, Metastatic Breast Cancer, Pancreatic Cancer, Gastric Cancer, Esophageal Cancer, Gastroesophageal Junction adenocarcinoma, Cervical Cancer, AAdenoid Cystic Carcinoma, Salivary Gland Cancer, Urothelial Carcinoma Learn more PRESERVE-006A Phase 2 study examining the safety and efficacy of gotistobart in combination with lutetium Lu 177 vipivotide tetraxetanIndications: Metastatic Castration-resistant Prostate Cancer Learn more PRESERVE-003A Phase 3 study of gotistobart versus docetaxelIndications: Non-Small Cell Lung Cancers that Progressed on PD-1/PD-l1 Inhibitors Learn more ONC-841-002Safety, Pharmacokinetics (PK) and Efficacy of ONC-841 in Advanced Solid Tumors NCT06352359Indications: Advanced or metastatic cancers Learn more Clinical trials recruiting soon For further inquiries about our clinical trials, don’t hesitate to reach out. Contact us